CBY2

Across TCGA pan-cancer cohorts, CBY2 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated CBY2 data layer compared with 9 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CBY2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CBY2 expression acts as an unfavorable survival marker, although some lineages such as THCA and BLCA show a favorable association.

LIHC, THCA, and HNSC are the cancer types where CBY2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.464	0.744	<.001	49	view →
THCA	DFS	Tertile	II,III,IV	0.913	0.633	.003	45	view →
HNSC	DFS	Tertile	All	0.259	0.454	.001	38	view →
KIRC	DFS	Quartile	II,III,IV	0.217	0.569	.002	24	view →
ACC	DFS	Tertile	II,III,IV	0.433	0.670	.026	21	view →
GBM	DFS	Median	All	0.204	0.303	.015	18	view →
PCPG	DFS	Tertile	All	0.289	0.874	.002	18	view →
BLCA	OS	Quartile	All	0.731	0.508	.001	15	view →
SARC	OS	Quartile	All	0.406	0.661	.005	14	view →
SCLC	OS	Quartile	II,III,IV	0.826	0.451	.018	11	view →
LGG	DFS	Tertile	All	0.375	0.479	.013	8	view →
LAML	DFS	Quartile	All	0.353	0.590	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

CBY2–LIHC (OS)

Open the LIHC breakdown →